  Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy…
Browsing: News
Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of…
Patients show improvements in blood vessels and physical ability after 8-week regimen — While exercise offers benefits for a wide range…
Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent…
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple…
Ayman A. Saad, MD of @OSUCCC_James answers commonly asked questions regarding the @NCCN guidelines debut to manage complications and actually…
Ayman A. Saad, MD of @OSUCCC_James discusses the @NCCN guidelines debut to manage complications and actually improve readiness for stem…
— First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in…
National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments. Today, the National Comprehensive Cancer Network® (NCCN®)…
A comparison of the Pinktober and Movember movements reveals that reach and engagement do not always lead people to research…
Company Commences First-in-Human Study at Multiple Academic Sites in United States Oct. 29, 2019 /PRNewswire/ — Linnaeus Therapeutics, Inc. (Linnaeus),…
Evidence from the lead program showed that glucocorticoids promote the growth of prostate tumor cells, stimulate androgen-regulated gene expression and…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM describes what is next and how this protein associated with many disease is visualized…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM answers common questions involving a protein associated with many disease is visualized for the…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM explains a protein associated with many disease is visualized for the first time. ___________…
New drugs can be motivated by understanding how receptors of P2X7 proteins function. Scientists first noticed how a protein associated…
(WASHINGTON, October 3, 2019) — Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions considers the future of artificial intelligence being used by…
Bruce Feinberg DO, VP Chief Medical Officer, Cardinal Health Specialty Solutions expresses some concerns surrounding artificial intelligence.
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions comments on how artificial intelligence may evolve into a…
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions discusses how artificial intelligence can increase efficiency and be…
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions showcases real-world examples of artificial intelligence being used by…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions explains the misunderstanding and complexity of artificial intelligence and…
Joan Brugge PhD Of Harvard Medical School Discusses The Process Of Tumor Genesis & Tumor Cells Response To Therapy: Its…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Questions About mRNA: Takes 50-60 Days From Biopsy To…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses How Did The Patients Do: Out Of 13 Patients…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Emerging Data For Personalized Vaccine Approach: Safety Profile Was…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Why Is CBX-11 Data Significant: Our Platform Technology Is Specific & Only Delivers…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses What Is Alphalex & How Does It Work: Makes Use Of Acidic Tumor…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Strategy Of Alphalex Developement: The Agnostic Nature Of The Platform Allows Us To…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses How Is Alphalex Different: Its An Antigen Agnostic Tumor Targeting Technology, Can Target…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Cybrexa Additional Candidates: CBX-11 Is The First Of Many Candidates, More Data Will…
Armon Sharei PhD Of SQZ Biotech Discusses Trial Addressing HPV Positive Tumors: Enrolling Patients In Trial This Year, Looking At…
Armon Sharei PhD Of SQZ Biotech Discusses SQZ Biotech: Engineer Multiple Facets Of Cell Function In A Very Practical Way,…
Armon Sharei PhD Of SQZ Biotech Discusses Questions About SQZ Biotech Technology: Use SQZ Platform To Deliver Antigens Directly Into…
Omid Hamid MD @OmidHamidMD Of The Angeles Clinic Discusses ASCO 2019 Data: Many Approvals In Solid Tumors, Responses In Patients…
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda In Depth, Enhancing Chemo & Radiotherapies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda & Isoflavonoid Studies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyondas Future In NSCLC, Sarcomas & Prostate Cancer.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Developing Isoflavone Idronoxil For Oncology Purposes.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Engineering EBV Specific T cells.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Mesothelin Targeted CAR-T Study.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses EBV CD19 CAR-T Cells Potency.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Subset Of 11 Mesothelioma Patients.
Vishwas Paralkar PhD, Cybrexa Chief Scientific Officer Discusses Combining Alphalex Technology With Rucaparib.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses What IRAK4 Degredation Offers.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses The Future Of The IRAK4 Degrader.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Protein Degradation Technology.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Elaborating On The IRAK4 Protein Degrader